Terminated PHASE3 INTERVENTIONAL 2-arm NCT00519090

Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENEST)

A Phase III Randomized, Open- Label Multi-center Study of Nilotinib Versus Imatinib in Adult Patients With Ph+ Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have a Suboptimal Cytogenetic Response (CyR) on Imatinib

Sponsor: Novartis Pharmaceuticals

Conditions Myelogenous Leukemia

Interventions Imatinib Nilotinib (AMN107)

Updated 9 times since 2017 Last updated: Nov 4, 2011 Started: Oct 31, 2007 Primary completion: Oct 31, 2008 Completion: Oct 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This study was terminated due to limited enrollment.

Other terminated trials from Novartis Pharmaceuticals

See all terminations from Novartis Pharmaceuticals

This PHASE3 trial investigates Myelogenous Leukemia and is currently terminated or withdrawn. Novartis Pharmaceuticals leads this study, which shows 9 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE3
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE3

▶ Show 4 earlier versions

Jan 2021 — Dec 2022 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Ann Arbor, United States , Baldwin Park, United States , Baltimore, United States , Barcelona, Spain , Beech Grove, United States , Berlin, Germany , Bethlehem, United States , Bologna, Italy , Bruges, Belgium and 69 more locations